{"name":"Fujifilm Healthcare","slug":"fujifilm","ticker":"4901","exchange":"TSE","domain":"fujifilm.com","description":"Fujifilm Holdings Corporation , trading as Fujifilm , or simply Fuji, is a Japanese multinational conglomerate headquartered in Tokyo, Japan, operating in the areas of photography, optics, office and medical electronics, biotechnology, and chemicals.","hq":"Tokyo, Japan","founded":1934,"employees":"~72,593","ceo":"Teiichi Goto","sector":"Healthcare & Life Sciences","stockPrice":3226,"stockChange":-56,"stockChangePercent":-1.71,"marketCap":"$24.6B","metrics":{"revenue":21224339722.350887,"revenueGrowth":6.8,"grossMargin":40.8,"rdSpend":0,"netIncome":1749649126.5207434,"cash":1078316464.2795618,"dividendYield":2.29,"peRatio":14.4,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Avastin patent cliff ($1.4B at risk)","drug":"Avastin","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-14","type":"earnings","headline":"Fujifilm Holdings Reports Fiscal 2023 Results","summary":"Fujifilm Holdings reported a net income of ¥143.8 billion for fiscal 2023, up 12.5% from the previous year.","drugName":"","sentiment":"positive"},{"date":"2023-09-01","type":"deal","headline":"Fujifilm Healthcare Partners with University of Tokyo to Develop AI-Powered Cancer Diagnosis","summary":"Fujifilm Healthcare has partnered with the University of Tokyo to develop an AI-powered cancer diagnosis system using its proprietary imaging technologies.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOVE9hS3Y4NXNrTmNtbDBNbWJHRHF0dHo5R3BuMl9oSEVBRGhaZ2ZWUVNkSVdBT2ZPMU9fQ0RpUGVOYm5fa25Sa2NsWElFRnR4S0l6b0pwcDh0ckJHZElocC1DaVZGb1JzcHpvZFhKWVBiXzg5TWQzZC1EazhqTWdGdHBaeENFVVdRemZLU0tSeDg0bkROcVBsc0ljd0JpWFZFYVk2TVFJWXJTUQ?oc=5","date":"2026-02-11","type":"pipeline","source":"The Pharma Letter","summary":"Fujifilm opens $500 million UK biologics facility - The Pharma Letter","headline":"Fujifilm opens $500 million UK biologics facility","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQRUtFMEtpSzduMElFVHlFR0pOZGhyTlRNcTZTdE1oWFpnSWItQnp5ODVFOWtqWV80LWRIZ29wV2pZT2pDZElLX0lwSGtqdU1XUDdzWWh4dU5pa0txZmpfaUJzYTI1QmltZWdYVDdxdF9iUW1wLWU4MWFaNWxhTkllZnQyNHlNS2VsamJNaURud0xNSnBzalBQLVd2bGphMlJJNXNGWV9zbWdERm1HZ3JfN0lFWl9CblJkU01YWVFLVQ?oc=5","date":"2019-12-17","type":"deal","source":"Reuters","summary":"Fujifilm to buy Hitachi's medical equipment business for $1.7 billion - Reuters","headline":"Fujifilm to buy Hitachi's medical equipment business for $1.7 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE9yd2JURlpBbWJfU21rdmxmWDFGb1BhdkdxNE1zU2RJXzBHWlh2X1BZZWFGWFE4dml1b2dWdTJKVTRZRXdyX1BWdEdpOVdSMTN6OVZibGZncko?oc=5","date":"2017-07-31","type":"pipeline","source":"TradingView","summary":"4901 Stock Price and Chart — TSE:4901 - TradingView","headline":"4901 Stock Price and Chart — TSE:4901","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPWVd0RnNfNHVNY2Fzd2haeHZ6TXZwbC0tRm1nZGdHNmh5SUtmUTV2MnhXVTBzaFlwbVd2UGtwd3JIZ28xeWp0Ri1Ja2hRbG1lS3RiQjdleTdBQTFEaFdkRGozZHg2ekFyMnRUWi16RUttLVZoOHpTZHdQeWpMUVNoNVhOR3FDYVFNWTdIU09TOXI3VnVwTFRR?oc=5","date":"2016-08-19","type":"pipeline","source":"MassDevice","summary":"Toshiba Medical Systems enters the race for Takeda’s chemicals subsidiary - MassDevice","headline":"Toshiba Medical Systems enters the race for Takeda’s chemicals subsidiary","sentiment":"neutral"}],"patents":[{"drugName":"Avastin","drugSlug":"bevacizumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1400000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Canon Medical Systems","Philips Healthcare","GE Healthcare"],"therapeuticFocus":["Oncology","Cardiovascular Diseases"],"financials":{"source":"yahoo_finance","revenue":20205531129.3192,"revenuePeriod":"2025-03-31","revenueHistory":[{"period":"2025-03-31","value":20205531129.3192},{"period":"2024-03-31","value":18720306727.8024},{"period":"2023-03-31","value":18076204953.9274},{"period":"2022-03-31","value":15969127555.392199}],"grossProfit":8219712295.2406,"grossProfitHistory":[{"period":"2025-03-31","value":8219712295.2406},{"period":"2024-03-31","value":7500094922.964},{"period":"2023-03-31","value":7194517235.2592},{"period":"2022-03-31","value":6532529189.7936}],"rdSpend":1033085504.2886,"rdSpendHistory":[{"period":"2025-03-31","value":1033085504.2886},{"period":"2024-03-31","value":993310836.7112},{"period":"2023-03-31","value":974589998.8958},{"period":"2022-03-31","value":951702652.4277999}],"sgaSpend":5099231245.885,"operatingIncome":2087395545.067,"operatingIncomeHistory":[{"period":"2025-03-31","value":2087395545.067},{"period":"2024-03-31","value":1749585898.165},{"period":"2023-03-31","value":1726534167.4406},{"period":"2022-03-31","value":1452284325.5228}],"netIncome":1649855234.3014,"netIncomeHistory":[{"period":"2025-03-31","value":1649855234.3014},{"period":"2024-03-31","value":1539578688.1426},{"period":"2023-03-31","value":1387289319.5307999},{"period":"2022-03-31","value":1335179510.2519999}],"eps":67.35,"epsHistory":[{"period":"2024-03-31","value":67.35},{"period":"2023-03-31","value":60.713333},{"period":"2022-03-31","value":175.37}],"cash":1088166875.1254,"cashHistory":[{"period":"2025-03-31","value":1088166875.1254},{"period":"2024-03-31","value":1136242947.651},{"period":"2023-03-31","value":1698266397.8112},{"period":"2022-03-31","value":3074794871.0192}],"totalAssets":33192393182.6312,"totalLiabilities":11995157124.3364,"totalDebt":5072423967.149,"equity":21170669033.472,"operatingCashflow":2707041999.5668,"operatingCashflowHistory":[{"period":"2025-03-31","value":2707041999.5668},{"period":"2024-03-31","value":2579195305.3873997},{"period":"2023-03-31","value":1330576751.0728},{"period":"2022-03-31","value":2048063450.4875998}],"capex":-3527970653.5569997,"capexHistory":[{"period":"2025-03-31","value":-3527970653.5569997},{"period":"2024-03-31","value":-2938128329.2367997},{"period":"2023-03-31","value":-2045142468.7008},{"period":"2022-03-31","value":-1048942262.5597999}],"freeCashflow":-820928653.9901999,"dividendsPaid":-431521317.9928,"buybacks":null,"employees":0,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":null,"ebitda":null,"period":"2025-12-31","revenue":null,"epsBasic":60.68465,"netIncome":null,"rdExpense":null,"epsDiluted":60.68465,"grossProfit":null,"operatingIncome":null},{"sga":null,"ebit":null,"ebitda":null,"period":"2025-09-30","revenue":null,"epsBasic":55.144941,"netIncome":null,"rdExpense":null,"epsDiluted":55.144941,"grossProfit":null,"operatingIncome":null},{"sga":null,"ebit":null,"ebitda":null,"period":"2025-06-30","revenue":null,"epsBasic":44.63,"netIncome":null,"rdExpense":null,"epsDiluted":44.59,"grossProfit":null,"operatingIncome":null},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-12-31","revenue":null,"epsBasic":59.12902,"netIncome":null,"rdExpense":null,"epsDiluted":59.12902,"grossProfit":null,"operatingIncome":null},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":41.144002,"netIncome":null,"rdExpense":null,"epsDiluted":41.144002,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":3226,"previousClose":3282,"fiftyTwoWeekHigh":3787,"fiftyTwoWeekLow":2855,"fiftyTwoWeekRange":"2855.0 - 3787.0","fiftyDayAverage":3029.37,"twoHundredDayAverage":3298.1,"beta":0.36,"enterpriseValue":30029773456.617348,"forwardPE":13.9,"priceToBook":1.01,"priceToSales":1.16,"enterpriseToRevenue":1.42,"enterpriseToEbitda":9.09,"pegRatio":0,"ebitda":3304003324.309943,"ebitdaMargin":15.6,"freeCashflow":-1686768173.6870034,"operatingCashflow":2595722186.145189,"totalDebt":6493260431.203696,"debtToEquity":26.7,"currentRatio":1.37,"returnOnAssets":3.9,"returnOnEquity":7.7,"analystRating":"2.0 - Buy","recommendationKey":"buy","numberOfAnalysts":13,"targetMeanPrice":3890.77,"targetHighPrice":5000,"targetLowPrice":3130,"dividendRate":75,"payoutRatio":0.31,"fiveYearAvgDividendYield":1.64,"exDividendDate":1790640000,"insiderHeldPercent":2.1,"institutionHeldPercent":48,"sharesOutstanding":1205329816,"floatShares":1204606618,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":224.49,"epsForward":232.05,"revenuePerShare":2789,"bookValue":3185.48,"officers":[{"age":71,"name":"Mr. Kenji  Sukeno","title":"Executive Chairman of The Board"},{"age":66,"name":"Mr. Teiichi  Goto","title":"President, CEO & Director"},{"age":62,"name":"Mr. Masayuki  Higuchi","title":"Corporate VP, GM of Corporate Planning Division, Accounting and Finance Div, CFO & Director"},{"age":62,"name":"Ms. Chisato  Yoshizawa","title":"Corporate VP, GM of Corp Communications and ESG Division-Global Audit Dep, Brand Mgmt & Director"},{"age":null,"name":"Atsushi  Sakurai","title":"Corporate VP & GM of Legal Division"},{"age":null,"name":"Yasushi  Zama","title":"Corporate VP and GM of Human Resources Division & Corporate General Administration Division"},{"age":85,"name":"Mr. Shigetaka  Komori","title":"Executive Advisor"},{"age":null,"name":"Seigo  Sugimoto","title":"Corporate VP, Chief Digital Officer & GM of ICT Strategy Office"}],"industry":"Conglomerates","irWebsite":"http://www.fujifilmholdings.com/en/investors/index.html","website":"https://holdings.fujifilm.com","phone":"81 3 6271 1111"}}